MedImmune's 4th-qtr income rises 7%
US biotechnology firm MedImmune says that its total revenue for full-year 2006 grew to $1.3 billion from $1.2 billion in the year before, while its fourth-quarter income rose 7% to $529.0 million, driven by gains in Synagis (palivizumab) and FluMist (influenza vaccine virus live, intranasal). These strong earnings saw the firm exceed its guidance for 2006, achieving net income of $75.0 million, or $0.30 per diluted share, excluding share-based compensation expenses.
In the fourth quarter of the year, global sales of Synagis, a treatment for respiratory infections, grew to $457.0 million from $439.0 million in the like, year-ago period, due to an increase in reported domestic sales to $403.0 million from $379.0 million in 2005. Income from FluMist increased 128% to $18.0 million and was up a massive 71% to $36.0 million for the year as a whole.
Sales of the firm's oncology product Ethyol (amifostine) reached $20.0 million in the fourth quarter of 2006 and $87.0 million for the full year versus $25.0 million and $95.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze